PPT-Peginterferon alfa-2b + Ribavirin
Author : danika-pritchard | Published Date : 2017-05-08
versus Interferon alfa2b Ribavirin Phase 3 Treatment Naïve Chronic HCV Manns MP et al Lancet 200135895865 Peginterferon alfa2b Ribavirin versus Interferon
Presentation Embed Code
Download Presentation
Download Presentation The PPT/PDF document "Peginterferon alfa-2b + Ribavirin" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Peginterferon alfa-2b + Ribavirin: Transcript
versus Interferon alfa2b Ribavirin Phase 3 Treatment Naïve Chronic HCV Manns MP et al Lancet 200135895865 Peginterferon alfa2b Ribavirin versus Interferon alfa2b Ribavirin . Alfa Laval is a leading global provider of specialized products and engineered solutions.. Our equipment, systems and services are dedicated to helping customers to optimize the performance of their processes. Time and time . Genotype . 1 . (. Viral . Relapsers. ). PROMISE . Trial. Phase . 3. Treatment. . Experienced. Forns. X. , . et al. . Gastroenterology. 2014;146:1669-79.e3.. Source: . Forns. X. , et al. Gastroenterology. 2014;146:1669-79.e3.. RBV . versus. . PEG alfa-. 2a . versus. INF + RBV . APRICOT STUDY. Phase 3. Treatment. . Naïve, Chronic HCV and HIV. Torriani. FJ, . et. al. N . Engl. J Med. . 2004;351:438-50. . PEG . + . RBV . versus . Telaprevir. . with PR in GT1 . ATTAIN Trial. Phase . 3. Treatment. . Experienced. Reddy KR. , . et al. . Lancet Infect Dis. 2015;15:27-35.. Source: Reddy KR. , et al. Lancet Infect Dis. 2015;15:27-35.. alfa-2a . versus. . Interferon . alfa-2a. Phase 3. Treatment. . Naïve, Chronic HCV. Zeuzem. S, et al. N . Engl. J Med. 2000;343:1666-72.. Source: . Zeuzem. S, . et al. . N Engl J Med. 2000;343:1666-72.. Overview. . of. . PECS . projects. European Space . Agency Information . Day. 1. 1. th. January. , 2017. Point of Contact: . Ms. . Maite. Trujillo: maite.trujillo@esa.int. Mr. Laurent . Marchand. Using . SiPM. to readout Scintillating Fibers . What has been done for ALFA. The “Scintillating Fibers & . SiPM. ” status of the art. . ALFA. . SiPM. Collecting Information. Starting discussion. Flat versus Weight-Based Ribavirin Dosing. Phase . 3. Treatment. . Naïve, Chronic HCV. Jacobson IM, et. al. Hepatology. 2007;46:971-81.. *Weight-based . ribavirin. dosing: < 65 kg: 800 mg/. d. . or 3 . LONESTAR-2. Phase 2. Treatment. . Experienced. Lawitz. . E, et al. . Hepatology. . 2015:61:769-75.. Source: . Lawitz. E, et al. . Hepatology. . . 2015:61:769-75.. Sofosbuvir + . PEG + RBV . RBV . versus. Interferon alfa. -. 2a + RBV . ACTG 5071. Phase . 2. Treatment. . Naïve, Chronic HCV and HIV. Chung RT, . et. al. N . Engl. J Med. . 2004;351:451-9. . PEG alfa. -2a . + . RBV . versus. . PEG alfa-. 2a . versus. INF RBV . APRICOT STUDY. Phase 3. Treatment. . Naïve, Chronic HCV and HIV. Torriani. FJ, . et. al. N . Engl. J Med. . 2004;351:438-50. . PEG . . RBV . versus. . PEG . . Interferon . alfa-2a. Phase 3. Treatment. . Naïve, Chronic HCV. Zeuzem. S, et al. N . Engl. J Med. 2000;343:1666-72.. Source: . Zeuzem. S, . et al. . N Engl J Med. 2000;343:1666-72.. Peginterferon alfa-2a versus Interferon alfa-. SPRINT. -1. Phase . 2. Treatment. . Naïve. Kwo. PY, et al. Lancet. 2010;376:705-16.. Source: . Kwo PY, et al. Lancet. 2010;376:705-16. .. Boceprevir . for Treatment-Naïve HCV Genotype 1. SPRINT. Following Liver Transplantation. Phase 2. Charlton M, . et al. . Gastroenterology. 2015;148:108-17.. Treatment. Naïve and Treatment . Experienced. Liver Transplantation. Source: Charlton M, et al. Gastroenterology. 2015;148:108-17..
Download Document
Here is the link to download the presentation.
"Peginterferon alfa-2b + Ribavirin"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.
Related Documents